These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 27259210)

  • 1. Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review.
    Khan N; Cox AR; Cotton JM
    Thromb Res; 2016 Jul; 143():141-8. PubMed ID: 27259210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Guimarães PO; Tricoci P
    Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary use of P2Y
    Rakowski T; Siudak Z; Dziewierz A; Plens K; Kleczyński P; Dudek D
    J Thromb Thrombolysis; 2018 Jan; 45(1):151-157. PubMed ID: 29075924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myocardial infarction: Role of new antiplatelet agents].
    Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
    Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
    Roffman DS
    J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
    Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F
    J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists.
    Hsin CH; Dingemanse J; Henrich A; Bernaud C; Gehin M; Krause A
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759765
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
    De Backer O; Ratcovich H; Biasco L; Pedersen F; Helqvist S; Saunamäki K; Tilsted HH; Clemmensen P; Olivecrona G; Kelbaek H; Jørgensen E; Engstrøm T; Holmvang L
    Thromb Haemost; 2015 Aug; 114(3):623-31. PubMed ID: 25994355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review.
    Bouatou Y; Samer CF; Fontana P; Daali Y; Desmeules J
    Curr Drug Metab; 2015; 16(2):97-104. PubMed ID: 26179606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
    Khan JN; Greenwood JP; Nazir SA; Lai FY; Dalby M; Curzen N; Hetherington S; Kelly DJ; Blackman D; Peebles C; Wong J; Flather M; Swanton H; Gershlick AH; McCann GP
    J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
    Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD
    Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
    Enar R
    Turk Kardiyol Dern Ars; 2013 Mar; 41(2):166-71. PubMed ID: 23666308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
    Qutub MA; Chong AY; So DY
    Can J Cardiol; 2015 Dec; 31(12):1481-4. PubMed ID: 26243350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
    Alexopoulos D; Bhatt DL; Hamm CW; Steg PG; Stone GW
    Am Heart J; 2015 Jul; 170(1):3-12. PubMed ID: 26093859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.